Home
Live Updates
AMO Pharma Announces Affirming Data from REACH-CDM Clinical Trial for AMO-02 in Treatment of Myotonic Dystrophy : comparemela.com
AMO Pharma Announces Affirming Data from REACH-CDM Clinical Trial for AMO-02 in Treatment of Myotonic Dystrophy
Results to be reviewed during 2023 Myotonic Dystrophy Annual Conference show statistically and clinically significant efficacy benefits in multipl...
Related Keywords
London ,
City Of ,
United Kingdom ,
Washington ,
United States ,
New Zealand ,
Australia ,
Canada ,
Kaitlin Gallagher ,
Meeting Of The Myotonic Dystrophy Foundation ,
Pharma Limited ,
Berry Company Public Relations ,
Commission On Human Medicines ,
Dystrophy Annual Conference ,
Myotonic Dystrophy Foundation ,
Renaissance Washington ,
Peabody Picture Vocabulary Test ,
Picture Sequence Memory Test ,
Dimensional Change Card Sort Test ,
Vineland Adaptive Behavior Communication Scale ,
Vineland Adaptive Behavior Daily Living Scale ,
Vineland Adaptive Behavior Socialization Scale ,
Human Medicines ,
comparemela.com © 2020. All Rights Reserved.